Gilbert & Cook’s Alnylam Pharmaceuticals ALNY Stock Holding History

Gilbert & Cook’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.18M	Sell	3,928 -32	-0.8%	-$9.65K	0.14%	70
2026 Q1	$1.31M	Sell	3,960 -58	-1%	-$19.7K	0.17%	54
2025 Q4	$1.6M	Sell	4,018 -1,490	-27%	-$659K	0.2%	45
2025 Q3	$2.51M	Buy	5,508 +1,514	+38%	+$617K	0.32%	24
2025 Q2	$1.3M	Buy	3,994 +90	+2%	+$24.9K	0.18%	55
2025 Q1	$1.05M	Hold	3,904	–	–	0.15%	60
2024 Q4	$919K	Sell	3,904 -20	-0.5%	-$5.26K	0.13%	74
2024 Q3	$1.08M	Sell	3,924 -137	-3%	-$35.7K	0.15%	65
2024 Q2	$987K	Sell	4,061 -424	-9%	-$66.9K	0.14%	65
2024 Q1	$670K	Buy	4,485 +42	+0.9%	+$7.01K	0.09%	106
2023 Q4	$850K	Buy	4,443 +317	+8%	+$54K	0.12%	77
2023 Q3	$731K	Buy	4,126 +2,766	+203%	+$528K	0.12%	82
2023 Q2	$258K	Buy	+1,360	New	+$270K	0.04%	184

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gilbert & Cook's ALNY Position: Q2 2026 in Review

Gilbert & Cook reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.81% in Q2 2026, selling an estimated $9.65K and leaving 3,928 shares worth $1.18M. The position accounts for 0.14% of the portfolio, ranked #70.

Gilbert & Cook first reported a position in ALNY in Q2 2023 and has held it in 13 quarters since. The position peaked at $2.51M in Q3 2025. 789 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Gilbert & Cook held 3,928 shares of Alnylam Pharmaceuticals worth $1.18M as of Q2 2026.
Gilbert & Cook sold 32 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $9.65K.
Alnylam Pharmaceuticals made up 0.14% of Gilbert & Cook's portfolio in Q2 2026, its #70 holding.
Gilbert & Cook first reported a position in Alnylam Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
Gilbert & Cook's Alnylam Pharmaceuticals position peaked at $2.51M in Q3 2025.
789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Gilbert & Cook's 13F filing for Q2 2026, filed 28 Jul 2026.